CSL Behring 新闻与活动
在场
CSL Behring由CSL所有。
是其中之一......
CSL 是一家在股票代码 CSL (AU) 下上市的公司。
CSL 在 11 个国家有直接业务。CSL 拥有 16家子公司，其中包括 CSL Behring、CSL Behring APAC 和 CSL Behring Asia。
他们在：
高管
查看带有其 30 名主要高管的组织结构图
CSL Behring 搜索最多的简介
- Paul McKenzie, Chief Executive Officer and Managing Director
- Tara Chapman, Executive Director and Head, Global Regulatory Affai...
- Bill Campbell, Executive Vice President and Chief Commercial Offic...
创建提醒
跟踪 CSL Behring 的高管变动
生物技术
CSL 拥有 2,349 家竞争者，其中包括 Astellas Gene Therapies (美国(美洲))、Eurofins (卢森堡) 和 Lonza (瑞士)。
Popular M&A news in 生物技术
- BioNTech has announced the acquisition of CureVac (公布2025六月12号).
- SpliceBio 刚刚宣布为 135 筹款数百万美元。 (公布2025六月11号).
- Antares Therapeutics 刚刚宣布为 177 筹款数百万美元。 (公布2025六月11号).
生物技术 行业的其他推荐联系人
消息
CSL Behring 的最新新闻稿
- England's NICE recommends FILSPARI® (sparsentan) as a treatment option for IgA nephropathy
- CSL Behring wins 2025 International Society for Pharmaceutical Engineering (ISPE) Facility of the Year Award
- CSL Seqirus, a Global Leader in Pandemic Preparedness and Outbreak Response, Signs an Agreement with the European Commission to Support Pandemic Preparedness Plans
- CSL Vifor and Travere Therapeutics announce standard EU approval for FILSPARI® in IgA Nephropathy
- CSL Launches ANDEMBRY® for the Prevention of Acute Attacks in Hereditary Angioedema (HAE) in Japan
- Influenza cases already at highest to date with vaccines now available
- CSL Seqirus and Esperion Sign Licensing Agreement to commercialise Nexletol® (bempedoic acid) and Nexlizet® (bempedoic acid/ezetimibe) in Australia and New Zealand
- Swissmedic Approves CSL Behring’s ANDEMBRY® (garadacimab) for the Prevention of Recurrent Attacks of Hereditary Angioedema (HAE)
- European Commission Approves CSL's ANDEMBRY® (garadacimab) for the Prevention of Recurrent Attacks of Hereditary Angioedema (HAE)
- CSL Behring's Gene Therapy HEMGENIX® (etranacogene dezaparvovec-drlb) Four Years Post-Infusion Data Continue to Show Sustained Efficacy and Safety in Adults with Hemophilia B
- View more press releases Close
